mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer (Adenocarcinoma)
Conditions
Keywords
talazoparib, enzalutamide, PARP inhibitor, TALENT, androgen receptor signaling inhibitor (ARSI), Prostate Cancer Clinical Trials Consortium, LLC (PCCTC), c24-349
Brief summary
The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate or darolutamide
Interventions
Talazoparib (0.5 mg PO QD) and enzalutamide (160 mg PO QD) will be administered in continuous 28-day cycles.
DRUGTalazoparib
Talazoparib (1 mg PO QD) will be administered in continuous 28-day cycles.
Sponsors
Prostate Cancer Clinical Trials Consortium
Pfizer
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
• Willing and able to provide, or have a legally authorized representative provide, written informed consent and privacy authorization for the release of personal health information. A signed informed consent must be obtained before screening procedures are performed. NOTE: Privacy authorization may be either included in the informed consent or obtained separately. * Participants ≥ 18 years of age. * Are willing to be randomized into either study arm and adhere to the study protocol. * Ability to swallow study capsules and/or tablets whole. * Are willing to remain on study treatment and to continue undergoing study imaging despite PSA progression unless clinically deteriorating. * Histological or cytological proof of predominant adenocarcinoma of the prostate. * Presence of a pathogenic homologous recombination repair mutation in at least one of the following genes: BRCA1, BRCA2, ATM (limited to 15% of enrolled participants), CDK12, CHEK2, PALB2, MLH1, NBN, ATR, FANCA, MRE11A, RAD51C. Assessment of HRR mutation status by germline or somatic testing. All testing must be per Clinical Laboratory Improvement Amendments (CLIA)-certified assay and may have occurred at any time prior to or at screening (not required to be completed within the screening window). * Metastatic castration-resistant prostate cancer (mCRPC) as demonstrated by one or both of the following: * Metastatic disease documented by conventional imaging: computed tomography (CT)/magnetic resonance imaging (MRI) chest/abdomen/pelvis and bone scan are required to be performed, but metastases do not need to be seen on both modalities. Measurable disease is not required. * Unequivocal prostate-specific membrane antigen (PSMA) positron emission tomography (PET) only defined metastatic disease with negative conventional imaging. PSMA PET imaging is not required to be performed, but may be used to document metastases when relevant. * Progressed either via a minimum of 2 rising PSA levels with a minimun of a 1-week interval between each determination or via radiographic progression by any form of imaging while receiving either abiraterone acetate with prednisone for mHSPC or locally advanced disease, OR darolutamide for mHSPC, locally advanced disease, or non-metastatic castration-resistant disease. * Progressive disease at start of treatment and in the setting of medical or surgical castration as defined by 1 or more of the following 4 criteria: * PSA progression defined as 2 rising PSA levels, above an initial reference value, taken with a minimum of a 1-week interval. If PSA rise is the only indication of progression at start of study treatment, a minimum PSA of 1.0 ng/mL is required and all measured PSA values have to be considered to make a determination of progression. * Soft tissue disease progression as defined by RECIST 1.1. * Bone disease progression defined by PCWG3 with 2 or more new metastatic bone lesions on a whole-body radionuclide bone scan. * Appearance of newly identified, convincingly positive lesion(s) consistent with metastatic prostate cancer on PSMA PET. * Surgically or medically castrated, with testosterone levels of \<50 ng/dL. If the participant is medically castrated, continuous dosing with a gonadotropin-releasing hormone agonist or antagonist must be demonstrated by testosterone level of \<50 ng/dL and planned to continue throughout study participation. * Eastern Cooperative Oncology Group (ECOG) status of ≤2 (Appendix A: Performance Status Criteria). * Normal organ function with acceptable initial laboratory values within 35 days of treatment start: * Absolute neutrophil count ≥ 1,500/µl * Hemoglobin ≥ 9g/dl * Platelet count ≥ 100,000/µl * Creatinine ≤ 1.5 x the institutional upper limit of normal (ULN) * Potassium ≥ 3.5 mmol/L (within institutional normal range) * Bilirubin ≤ 1.3 x ULN (unless documented Gilbert's disease) * Serum glutamic oxaloacetic transaminase/aspartate transaminase (AST) ≤ 2.5 x ULN * Serum glutamic pyruvic transaminase/ alanine transaminase (ALT) ≤ 2.5 x ULN * Participants must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 4 months after the last dose of study drug. Sperm donation is prohibited during the study and for 4 months after the last dose of study drug. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent.
Exclusion criteria
* Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 2 years prior to first dose of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer or superficial bladder cancer. * Prior treatment for metastatic CRPC with an ARPI for ≥ 12 weeks. * Prior treatment for non-metastatic CRPC with abiraterone acetate with prednisone, enzalutamide, or apalutamide for ≥ 12 weeks. * Participants who received chemotherapy for castration-sensitive prostate cancer are still eligible provided chemotherapy was completed ≥ 28 days prior to start of study treatment. * Participants who received PLUVICTO® for castration-sensitive prostate cancer are still eligible provided treatment was completed ≥ 42 days prior to start of study treatment. * Use of investigational agents for the treatment of prostate cancer ≤ 28 days of start of study treatment. * Prior treatment with a PARP inhibitor. * Concurrent treatment with crizotinib. * Prior platinum-based chemotherapy for the treatment of prostate cancer. * Current or planned use of potent P-gp inhibitors within 7 days prior to randomization. The P-gp inhibitors include: amiodarone, carvedilol, clarithromycin, cobicistat, dronedarone, erythromycin, glecaprevir/pibrentasvir, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, sofosbuvir/velpatasvir/voxilaprevir, telaprevir, tipranavir, valspodar, and verapamil. * Participants treated within 7 days of randomization with any medication that may result in a drug-drug interaction with study treatment, including strong CYP2C8 inhibitors or inducers; strong or moderate CYP3A4 inducers or substrates of CYP3A4, CYP2C9, or CYP2C19 with a narrow therapeutic index unless considered medically necessary to treat a life-threatening condition. Examples include, but are not limited to, clopidogrel, gemfibrozil, rifampin, carbamazepine, phenobarbital, phenytoin, rifabutin, rifapentine, St. John's Wort, bosentan, efavirenz, etravirine, modafinil, nafcillin, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, warfarin, and S-mephenytoin. * Use of hormonal agents with known or potential anti-tumor activity against prostate cancer within 28 days prior to the start of study treatment is prohibited. This includes, but is not limited to, 5-alpha reductase inhibitors, androgens such as testosterone, cyproterone acetate, progestational agents, estrogens, and diethylstilbestrol. * Use of herbal products, nutritional supplements, or alternative therapies that may decrease PSA levels within 28 days prior to initiation of study treatment or plans to initiate treatment with these products/alternative therapies during the entire duration of the study. Examples include but are not limited to, saw palmetto, selenium supplements, and grape seed extract. * Participants receiving a blood transfusion within 14 days of randomization are not eligible. * History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma). Also, history of loss of consciousness or transient ischemic attack within 12 months of randomization. * Medical conditions such as uncontrolled hypertension as indicated by a resting systolic blood pressure \> 160 mm Hg or diastolic blood pressure \> 90 mm Hg at screening, uncontrolled diabetes mellitus, and cardiac disease that would preclude participation, as determined by the investigator. * Untreated known or suspected brain metastases or spinal cord compression or clinically significant malignant epidural disease. * Use of any prohibited concomitant medications (Appendix C: Medications with the Potential for Drug-Drug Interactions) within 28 days before first dose of study treatment unless otherwise specified as 7 days. * Grade \>2 treatment-related toxicity from prior therapy except alopecia or peripheral neuropathy. * Known allergy to any of the compounds under investigation. * Any other condition which, in the opinion of the Investigator, would preclude participation in this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| radiographic progression free survival (rPFS) | From treatment initiation until documented disease progression, death, lost to follow-up, withdrawal, administrative censoring at the time of final analysis, assessed at approximately 42 months from the start of enrollment. | To compare the efficacy of talazoparib + enzalutamide to talazoparib alone as measured by rPFS as assessed by the Investigator. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to PSA50 | Time from treatment initiation until observed PSA50, assessed at approximately 42 months from the start of enrollment. | To compare the efficacy of talazoparib + enzalutamide to talazoparib alone as measured by time to prostate specific antigen (PSA) ≥ 50% decline, summarized using median time-to-event and landmark response rates at 9 and 12 months. |
| Time to PSA Progression | From treatment initiation until documented PSA progression, assessed at approximately 42 months from the start of enrollment. | To compare the efficacy of talazoparib + enzalutamide to talazoparib alone as measured by time to PSA progression. |
| Quality of Life (QoL) by Functional Assessment of Cancer Therapy-Prostate (FACT-P) | From prior to treatment initiation (screening) until treatment discontinuation, assessed at approximately 42 months from the start of enrollment. | Overall QoL measured by FACT-P. Scales: FACT-P Total score (range 0-156), FACT-General (G) Total score (range 0-108), FACT-P Trial Outcome Index (TOI) score (range 0-104). The higher the score, the better the QOL. |
| Quality of Life (QoL) by Functional Assessment of Cancer Intervention Therapy-Fatigue Scale (FACIT-Fatigue) | From prior to treatment initiation (screening) until treatment discontinuation, assessed at approximately 42 months from the start of enrollment. | Fatigue measured by FACIT-Fatigue. Scales: FACIT-F Total score (range 0-160), FACT-General (G) Total score (range 0-108), FACIT-F Trial Outcome Index (TOI) score (range 0-108). The higher the score, the better the QOL. |
| Quality of Life (QoL) by Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) | From prior to treatment initiation (screening) until treatment discontinuation, assessed at approximately 42 months from the start of enrollment. | Cognitive function measured by FACT-Cog. Subscales: Perceived Cognitive Impairments (CogPCI) score (range 0-72), Impact of Perceived Cognitive Impairments on Quality of Life (CogQOL) score (range 0-16), Comments from Others (CogOth) score (range 0-16), Perceived Cognitive Abilities (CogPCA) score (range 0-28). The higher the score, the better the QOL. |
| Adverse Events (AE) | From treatment initiation through follow up, up to 12 months from end of treatment, assessed at approximately 42 months from the start of enrollment. | Evaluate AE occurrence according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 to confirm safety. |
| Overall Survival (OS) | From treatment initiation until death, lost to follow-up, withdrawal, administrative censoring at the time of final analysis, assessed at approximately 42 months from the start of enrollment. | To compare the efficacy of talazoparib + enzalutamide to talazoparib alone as measured by OS. |
Countries
United States
Contacts
CONTACTSarah Wise
PRINCIPAL_INVESTIGATORAlicia Morgans, MD
Dana-Farber Cancer Institute
Outcome results
None listed